Join FierceBiotech Executive Editor, Ryan McBride, and a panel of industry experts from AstraZeneca, New Enterprise Associates (NEA) and Third Rock Ventures as they discuss the impact of the much-hyped Big Data phenomenon on their biopharma operations and investment plans.
Drug developers have more data analytics and computational tools at their disposal than ever before, and there are some solid examples of how the technologies have aided some companies and CROs in tackling risky R&D programs efficiently. The challenge is evaluating what is important and what isn’t.
Key topics to be covered during this lively roundtable discussion include:
- Current and future impacts of Big Data in drug development
- Intelligently advancing drug research with new IT advances
- Insights on new biotech ventures leveraging computational and analytical capabilities
- Analyses on the role of vendors and service partners in supporting research
FierceBiotech executive breakfasts provide attendees with a unique opportunity to hear an insider perspective in an uncensored environment, while enjoying high-level networking.
Registration & Networking: —
Breakfast & Program: —
Location: Hotel Nikko, San Francisco, CA